Dr. Barry Dworkin

Pembrolizumab given to patients with stage two or three bowel cancer and a certain genetic profile (MMR deficient/MSI-High bowel cancer) before surgery instead of chemotherapy led to a significant increase in patients being declared cancer-free, a UK clinical trial found.

Medical Mythbusting Commentary for June 3, 2024

Source:
Drug that ‘melts away’ tumours hailed as ‘gamechanger’ for some bowel cancer patients

Related posts:

  1. Colon cancer screening with sigmoidoscopy shown to be effective: Lancet-published study
  2. Preliminary observations between statin medications and colon cancer risk reduction
  3. Biomarkers used to screen for colon cancer
  4. New medication for Hodgkin's patients who have failed to respond to all other treatments may soon be approved